Join our community of smart investors

Long Covid: Why GSK may have played a better vaccine game than AstraZeneca

Covid-19 vaccine profits will come to the most patient companies
Long Covid: Why GSK may have played a better vaccine game than AstraZeneca
  • AstraZeneca has received backlash from the EU for delays in vaccine supply
  • GSK is set to redouble its efforts in 'next generation' vaccine manufacture

Vaccine nationalism shouldn’t have come as a surprise. Trouble has been brewing ever since Vladimir Putin named the Russian jab after the victorious space race satellite, Sputnik; Donald Trump called on historians to remember that the successful trial results from US companies Pfizer (US:PFE) and Moderna (US:MRNA) took place on ‘his watch’; and Boris Johnson signed a deal with AstraZeneca (AZN) which stipulated that vaccines made in the UK would be offered to Britain first.

It is perhaps a surprise that the European Union has been the first to crack. But then, the bloc is only just recovering from its Brexit bruises and perhaps its poor vaccine rollout compared with the country from which it has just completed a very public divorce has rubbed too much salt in a fresh wound. At the time of writing, 12.5 per cent of Brits have been given their first vaccine dose, compared with 2.5 per cent of the population of the EU.  

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in